Bortezomib (Velcade)-thalidomide-dexamethasone is superior to thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation

AllImages Books News Maps Videos Shopping

Current Trial Consolidation Therapy with Bortezomib/Lenalidomide ...

www.sciencedirect.com › science › article › abs › pii

... autologous bone marrow transplantation and chemotherapy in multiple myeloma. ... Bortezomib (Velcade)-thalidomidedexamethasone (VTD) vs thalidomide-dexamethasone�...

Bortezomib for the Treatment of Hematologic Malignancies

link.springer.com › Drugs in R&D

Apr 16, 2019 � The VTD regimen has been shown to be superior to thalidomide and dexamethasone in patients relapsed after ASCT [77]. However, the presence of�...

Bortezomib, thalidomide, and dexamethasone as induction therapy ...

acsjournals.onlinelibrary.wiley.com › doi › cncr

Apr 14, 2010 � This single-center retrospective study determined the efficacy of bortezomib, thalidomide, and dexamethasone (BTD) as induction for patients�...

[PDF] VELCADE - Medsafe

www.medsafe.govt.nz › profs › datasheet › Velcadeinj

Following stem cell transplantation, patients receive two 5-week cycles of VELCADE-thalidomide- dexamethasone. The treatment regimen is shown in Table 1. Table�...

Bortezomib (velcade)-thalidomide-dexamethasone (VTD) is superior ...

www.muni.cz › V�zkum › Publikace

Bortezomib (velcade)-thalidomide-dexamethasone (VTD) is superior ... patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation�...

relapsed/refractory multiple myeloma | Клиническая онкогематология

old.bloodjournal.ru › tag › relapsed-refractory-multiple-myeloma

... patients with multiple myeloma relapsing after autologous transplantation ... Bortezomib (VELCADE)-thalidomide-dexamethasone (VTD) is superior to thalidomide�...

Emerging Therapies for Multiple Myeloma - Cancer Network

www.cancernetwork.com › view › emerging-therapies-multiple-myeloma

Apr 30, 2009 � 04). The patients on the thalidomide arm had a higher 3-year progression-free survival (85% vs 57%, P = .02) and overall survival (85% vs 65%, P�...

Thalidomide / Dexamethasone (TD) Vs. Bortezomib (Velcade)� ...

www.semanticscholar.org › paper

The primary end points were response rate after induction and after ASCT and time to progression and prognostic factors, including cytogenetics,�...

Superiority of the triple combination of bortezomib ...

www.htct.com.br › en-superiority-triple-combination-bortezomib-cyclopho...

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation�...

Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) is ...

air.unimi.it › handle

... dexamethasone (TD) in patients with multiple myeloma (MM) progressing or relapsing after autologous transplantation. L. Garderet;S. Iacobelli;P. Moreau;M�...